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aBstraCt
This case study concerns a 53-year-old female presenting to an eye-hospital in London with uveitis, on a background 
of well-controlled HIV. After investigation, no cause for the uveitis was found other than the HIV itself, and the pa-
tient was treated with immunosuppressants. Because of the nature of her underlying HIV infection, help was sought 
from HIV specialists, who gave advice on the management, including alteration of corticosteroid dosing due to the 
risk of drug-interactions between her uveitis and HIV treatments. Of particular concern was the risk of cytochrome 
P450 3A inhibition by cobicistat and the potential for iatrogenic Cushing syndrome through elevated steroid doses. 
This case is used as an example to highlight the importance of the multi-disciplinary team in the management of 
complex conditions, as well as to add to the literature in support of the HIV virus itself as a cause of uveitis.
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Case presentation
A 53-year-old Afro-Caribbean female with 
a background of well-controlled human immuno-
deficiency virus (HIV) suffered subacute onset left 
sided ocular pain and loss of vision.
One year prior to presentation, she had a sus-
pected reactivation of ocular (retinal) toxoplasmosis 
treated appropriately. Diagnosed over 25 years ago, 
her HIV was known to be triple-class antiretroviral 
drug resistant (TC-DR). Despite extensive antiret-
roviral therapy changes, she was well controlled 
on Symtuza (combination of darunavir, cobicistat, 
emtricitabine, and tenofovir alafenamide) at the 
time of presentation. Her most recent CD4 count 
was 840 cells/mm3 with an undetectable HIV-1 vi-
ral load.
At presentation with a five-day history of wors-
ening ocular pain, floaters, and loss of vision, her 
left intraocular pressure (IOP) was 42 mmHg, and 
her visual acuity was CF in the affected eye. Exten-
sive corneal oedema was present (Fig. 1) with iris 
bombe demonstrated in three quadrants as well as 
a large crystalline lens on B-scan ocular ultrasound. 
With no clinical fundal view, B-scan also showed 
a retinal traction band expanding temporally with 
no retinal detachment. A diagnosis of hypertensive 
uveitis and iris bombe was made, with particular 
note of the immunocompromised state. 
She had no other systemic symptoms. In par-
ticular, she had no weight loss, fever, night sweats, 
rashes, or cough, which could point to an aetiology. 
There was no history of, or high-risk contact with, 
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mycobacterium tuberculosis (TB). Extra-ocular 
clinical examination was within normal limits, with 
no lymphadenopathy.
Intraocular pressure lowering was immediately 
attempted with intravenous acetazolamide. Topi-
cal carbonic anhydrase inhibitor, beta blockers, 
anti-muscarinic, prostaglandin analogues, and al-
pha agonists [dorzolamide and timolol (Cosopt), 
atropine, latanoprost and iopidine, respectively]
were also administered to aid this. Oral and topical 
steroids were started to treat the uveitis, the under-
lying cause of the raised IOP and loss of vision. As 
she was on a protease inhibitor, this was all in close 
discussion with the HIV team and specialist phar-
macists, to prevent adverse effects on HIV control. 
Anti-emetics, analgesics, and benzodiazepines were 
also prescribed for symptom relief. 
Over three days, her ocular pain settled, intraoc-
ular pressure reduced to 10 mm Hg, and she was 
discharged with a reducing regime of oral pred-
nisolone as well as a topical steroid and non-steroi-
dal anti-inflammatory drops as a steroid-sparing al-
ternative. Unfortunately, her visual acuity remained 
CF in the left eye despite treatment.
In the following two months, her IOP became 
persistently high at 34 mm Hg despite oral aceta-
zolamide. An emergency micropulse diode laser 
trabeculoplasty (MDLT), using laser to alter the 
trabecular network and aid flow of the aqueous 
humour and thus reduce IOP, was successfully per-
formed. Due to persistent inflammation, a dense 
cataract has formed. She now awaits a surgical irid-
ectomy and cataract surgery with intravitreal steroid 
to open up the iridocorneal angle further and im-
prove visual acuity. 
Despite extensive testing, no cause of the ae-
tiology of her uveitis was found. Her repeated 
HIV-1 viral load was less than 20 and CD4 count 
373 cells/mm3. 
Throughout her treatment, the HIV team were 
very closely involved. Whilst on immunosuppressive 
steroids, it was decided to intensify her current HIV 
therapy with the addition of dolutegravir, an inte-
grase inhibitor. She remains systemically well from 
an HIV perspective at present, and ongoing col-
laborative care remains essential because long-term 
immunosuppression for ocular pathology is likely.
disCussion
This patient presented with uveitis (inflamma-
tion of the iris, ciliary body, and choroid) leading 
to raised IOP after developing iris bombe. This is 
where inflammation causes the iris to become ad-
herent to the crystalline lens, preventing aqueous 
humour outflow. Raised IOP is dangerous due to 
its potential to cause irreversible optic neuropathy 
(glaucoma). 
Uveitis is associated with many conditions in-
cluding autoinflammatory disorders, infectious dis-
eases, or it may be idiopathic. HIV is a disease com-
monly associated with uveitis, and it is estimated 
that 70–80% of patients with untreated HIV will 
develop an ocular condition at some point, of which 
half will be inflammation or uveitis [1]. 
Uveitis and other ocular complications of HIV 
are typically caused by opportunistic infections such 
as tuberculosis, syphilis, and toxoplasmosis, as well 
as malignant processes such as lymphoma secondary 
to progressive immune dysfunction. However, there 
Figure 1. affected eye showing significant corneal oedema
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are also reports of uveitis occurring in HIV-infected 
patients without any suspected causative agents oth-
er than the HIV virus itself [2, 3]. This implicates 
that the eye itself could be a sanctuary for HIV. 
Certain drugs used to treat HIV are also associ-
ated with a risk of uveitis, particularly medications 
containing rifabutin [4] or cidofovir [5]. Symtuza, 
however, is not associated with this risk. Only one 
published study has found a weak link between 
a similar class of medication containing three of 
the four constituent drugs and uveitis. In all cases, 
the uveitis resolved without stopping the drug [6]. 
Given no evidence to the contrary, it is likely that 
the HIV infection itself was the causative organism 
in this case, although intraocular fluid was not sent 
for culture to confirm this.
Anterior uveitis in HIV tends to be asympto-
matic [7]. A case series of symptomatic uveitis in 
HIV found four other patients over a four-year 
period in one hospital with CD4 counts over 
200 cells/mm3 and symptomatic uveitis with no 
concurrent illness [7]. Other symptomatic cas-
es, which were associated with other aetiologies, 
such as tuberculosis and herpes zoster, all had 
CD4 counts < 200 cells/mm3.
This case highlights the comparative rarity of 
a patient with well-controlled HIV developing 
a symptomatic uveitis without clear underlying ae-
tiology, as well as the importance of cooperation 
between ophthalmic and infectious disease special-
ists in the treatment of this condition.
The mainstay of treatment of non-infective uvei-
tis is corticosteroids, which can be given via several 
routes, commonly topical and oral [8]. They need 
slow tapering over a period of weeks so as not to 
cause rebound inflammation when they are with-
drawn. Drugs to paralyse the ciliary body are also 
given to relieve pain and prevent adhesions. If an 
infective cause is suspected, an appropriate antimi-
crobial is also added.
Despite the theoretical concerns over the use of 
immunosuppressive drugs such as corticosteroids in 
patients who are already immunosuppressed, studies 
have shown that short-term steroid use in HIV-pos-
itive individuals is relatively safe, well tolerated, and 
not associated with effects on HIV-1 RNA levels 
or CD4 cell counts [9, 10]. Corticosteroid use is 
generally only a concern when high doses are used, 
or when the CD4 count is very low [11].
The issue with co-prescribing corticosteroids in 
patients being treated for HIV is not therefore a risk 
of worsening HIV control; instead, care must be 
taken due to drug-drug interactions between cor-
ticosteroids and HIV treatments. Cobisistat, one 
of the components of Symtuza, acts as a boosting 
agent for the effects of the protease inhibitor daru-
navir. Its main mechanism of action is inhibition 
of the enzyme cytochrome P450 3A (CYP3A), the 
liver enzyme that breaks down darunavir [12]. In-
hibition of this enzyme therefore leads to increased 
levels and prolonged effects of darunavir. Many 
other drugs are also metabolised by CYP3A, the 
most relevant of which in this case are corticos-
teroids. Through the same mechanism of action, 
Cobisistat therefore increases plasma concentrations 
of corticosteroids given as treatment for uveitis and 
could risk development of steroid-associated side 
effects. This includes Cushing syndrome and sec-
ondary adrenal suppression through the hypotha-
lamic-pituitary-adrenal axis.
There has been a reported case of this occurring 
in a patient on a CYP3A inhibitor and corticoster-
oid eye drops, which led to serious complications 
including avascular necrosis of the hip [13]. Con-
versely, there is also a theoretical risk that the steroid 
(dexamethasone) eye drops could alter the efficacy 
of the protease inhibitor darunavir. This is because 
dexamethasone can act as an inducer of the CYP3A 
enzyme, of which darunavir is a substrate, which 
could worsen HIV control [14]. Accordingly, care 
must be taken when co-prescribing these medica-
tions because they have the potential to cause seri-
ous, irreversible side-effects as well as the worsening 
of underlying HIV control. Specialists must thus be 
involved to ensure safe prescribing. 
In our patient, the dose of oral corticosteroids 
was reduced by a third to compensate for the in-
creased systemic exposure. Punctal occlusion was 
also taught to minimise systemic absorption of 
topical dexamethasone drops. The decision was also 
made to intensify HIV treatment with the addition 
of dolutegravir to counteract the potential reduction 
in efficacy through the induction of darunavir. Do-
lutegravir is not primarily metabolised by CYP3A 
and is therefore not subject to the same drug inter-
actions discussed here [15]. 
Without input from multi-disciplinary special-
ists, this patient could have been at greater risk of 
serious iatrogenic complications.
ConClusion
This case showcases that ocular inflammatory 
emergencies, such as iris bombe, can present in the 
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absence of obvious causal aetiology, and it adds to 
the literature in support of the HIV-1 virus itself 
as a cause of uveitis. Multi-disciplinary teamwork 
is key in the management of complex uveitis, es-
pecially with immunosuppressed individuals on 
medications pre-disposing to dangerous drug-drug 
interactions. 
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